Stem cell medications hold the power to improve the quality of life and extend longevity


Stem Cell Medicine enjoys cooperation and collaboration with a number of academic and commercial institutions, including:

  • Licensing of technology developed by Dr. Arnon Karni, Tel Aviv Sourasky Medical Center (TASMC) and research collaboration on novel mechanism of action utilizing anti-BMP small molecules for the treatment of multiple sclerosis (MS)
  • Licensing of a novel treatment for neuronal diseases based on genetically modified muscle progenitor cells (MPCs) that secrete neurotropic factors (NTFs) from Ramot at Tel Aviv University Ltd. and Weizmann Institute’s Yeda Research and Development Company Ltd. 
  • A sponsored research program with Ramot at Tel Aviv University Ltd. on mesenchymal cell-derived exosomes for the treatment of autism (NOFAR program, under the Israel Innovation Authority) 
  • Collaborations on several products with Mapi Pharma, including the manufacturing of Finolim (Fingolimod, Gilenya™), an oral generic product for the treatment of MS currently sold in the Israeli market

The company welcomes partnership opportunities in the form of research collaborations or with companies that have products in development stages and early clinical development.